Wound Care Innovations (WCI), a subsidiary of Wound Management Technologies, has signed a distribution agreement with Bivium International to distribute its advanced wound care collagen product Cellerate RX in Panama.

Bivium plans to introduce Cellerate RX to the Panamian health-care community at the Congress of the Panamanian Association of General Surgery conference in Panama City.

The addition of Panama puts WCI’s distribution channels in 6 countries in Central America, including Belize, El Salvador, Honduras, Nicaragua and Guatemala.

WCI president Cathy Bradshaw said that they are extremely excited to see the growth of Cellerate RX in the Central American region and Cellerate RX is FDA cleared for use on all acute and chronic wounds except 3rd degree burns and so many will benefit from having it available.

“It has been found to be very effective in managing diabetic wounds, a problem in this region as well as throughout the world,” Bradshaw said.